SCHEMBL10162458

SCHEMBL10162458

CC(=O)c1ccc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(F)c3)nc3ncnn23)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 7/20 0.44
CACNA1G O43497 4/20 0.42
CACNA1H O95180 4/20 0.42
CACNA1I Q9P0X4 4/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
MMP10 P09238 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MET P08581 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 1/20 0.39
PTGER4 P35408 1/20 0.39
PDPK1 O15530 1/20 0.39
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
PDGFRA P16234 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162443 0.93 MMP13 (0.55) MMP13MMP10MMP9MMP8L3MBTL1
SCHEMBL10162454 0.92 MMP13 (0.42) MMP13MMP10MMP9MMP8L3MBTL1
SCHEMBL10162335 0.90 CACNA1G (0.43) MMP13CACNA1GCACNA1HCACNA1IMAOA
SCHEMBL10162500 0.86 MMP13 (0.40) MMP13CACNA1GCACNA1HCACNA1IMAOB
SCHEMBL10162460 0.85 MMP13 (0.45) MMP13CACNA1GCACNA1HCACNA1IMAOA
SCHEMBL10165795 0.85 MMP13 (0.63) MMP13CACNA1GCACNA1HCACNA1IMMP10
SCHEMBL8247491 0.85 MMP13 (0.59) MMP13MMP10MMP9MMP8L3MBTL1
SCHEMBL8183920 0.84 MMP13 (0.52) MMP13CACNA1GCACNA1HCACNA1IMAOB
SCHEMBL8181299 0.84 PDE2A (0.47) MMP13CACNA1GCACNA1HCACNA1IMET
SCHEMBL8256094 0.83 MMP13 (0.58) MMP13MMP10MMP9MMP8L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885CACNA1G 2170/4885CACNA1H 2465/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885CACNA1G 2170/4885CACNA1H 2465/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885CACNA1G 2170/4885CACNA1H 2465/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885CACNA1G 2170/4885CACNA1H 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.